HKD 9.64
(4.1%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 784.53 Million CNY | 14.88% |
2022 | 682.9 Million CNY | 15.71% |
2021 | 590.17 Million CNY | 18.32% |
2020 | 498.78 Million CNY | 524.89% |
2019 | 79.82 Million CNY | -82.85% |
2018 | 465.35 Million CNY | 17.44% |
2017 | 396.24 Million CNY | 28.85% |
2016 | 307.52 Million CNY | 23.16% |
2015 | 249.68 Million CNY | 18.22% |
2014 | 211.2 Million CNY | 38.15% |
2013 | 152.88 Million CNY | 12.24% |
2012 | 136.2 Million CNY | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 399.76 Million CNY | 0.0% |
2023 FY | 784.53 Million CNY | 14.88% |
2023 Q4 | 436.64 Million CNY | 0.0% |
2023 Q2 | 347.89 Million CNY | 0.0% |
2022 Q2 | 296.72 Million CNY | 0.0% |
2022 FY | 682.9 Million CNY | 15.71% |
2022 Q4 | 386.17 Million CNY | 0.0% |
2021 Q2 | 250.64 Million CNY | 0.0% |
2021 FY | 590.17 Million CNY | 18.32% |
2021 Q4 | 339.52 Million CNY | 0.0% |
2020 Q4 | 289.9 Million CNY | 0.0% |
2020 FY | 498.78 Million CNY | 524.89% |
2020 Q2 | 208.88 Million CNY | 0.0% |
2019 Q4 | -169.65 Million CNY | 0.0% |
2019 FY | 79.82 Million CNY | -82.85% |
2019 Q2 | 249.47 Million CNY | 0.0% |
2018 Q4 | 246.33 Million CNY | 0.0% |
2018 Q2 | 219.01 Million CNY | 0.0% |
2018 FY | 465.35 Million CNY | 17.44% |
2017 Q2 | 184.81 Million CNY | 0.0% |
2017 FY | 396.24 Million CNY | 28.85% |
2017 Q4 | 211.42 Million CNY | 0.0% |
2016 Q4 | 162.12 Million CNY | 0.0% |
2016 FY | 307.52 Million CNY | 23.16% |
2016 Q2 | 145.39 Million CNY | 0.0% |
2015 Q2 | 121.19 Million CNY | 0.0% |
2015 FY | 249.68 Million CNY | 18.22% |
2015 Q4 | 128.49 Million CNY | 0.0% |
2014 Q2 | 90.82 Million CNY | 0.0% |
2014 Q4 | 120.37 Million CNY | 0.0% |
2014 FY | 211.2 Million CNY | 38.15% |
2013 Q4 | 93.81 Million CNY | 0.0% |
2013 FY | 152.88 Million CNY | 12.24% |
2013 Q2 | 59.06 Million CNY | 0.0% |
2012 Q3 | 34.05 Million CNY | 0.0% |
2012 Q4 | 38.22 Million CNY | 12.24% |
2012 Q2 | 34.05 Million CNY | 0.0% |
2012 Q1 | 34.05 Million CNY | 0.0% |
2012 FY | 136.2 Million CNY | 0.0% |
2011 Q4 | 34.05 Million CNY | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Pak Fah Yeow International Limited | 105.03 Million HKD | -646.898% |
Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 58.269% |
Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 581.46% |
Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 5208.974% |
Qianhai Health Holdings Limited | -52.7 Million HKD | 1588.538% |
Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -4598.371% |
Essex Bio-Technology Limited | 275.25 Million HKD | -185.016% |
Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 2820.015% |
PuraPharm Corporation Limited | -106.08 Million HKD | 839.561% |
SSY Group Limited | 1.31 Billion HKD | 40.503% |
JBM (Healthcare) Limited | 130.46 Million HKD | -501.346% |
Jacobson Pharma Corporation Limited | 266.96 Million HKD | -193.868% |
China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 79.645% |